Yilan Hu

ORCID: 0009-0003-3847-6602
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Extracellular vesicles in disease
  • Neuroscience and Neuropharmacology Research
  • Heart Failure Treatment and Management
  • Nanoplatforms for cancer theranostics
  • MicroRNA in disease regulation
  • Pulmonary Hypertension Research and Treatments
  • Helicobacter pylori-related gastroenterology studies
  • Tissue Engineering and Regenerative Medicine
  • Ubiquitin and proteasome pathways
  • Sarcoma Diagnosis and Treatment
  • Vascular Tumors and Angiosarcomas
  • Advanced biosensing and bioanalysis techniques
  • Genetics and Neurodevelopmental Disorders
  • Gut microbiota and health
  • Parasites and Host Interactions
  • Monoclonal and Polyclonal Antibodies Research
  • Cutaneous lymphoproliferative disorders research
  • HIV Research and Treatment
  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 and COVID-19 Research
  • Photoacoustic and Ultrasonic Imaging

Columbia University
2024

Chinese Academy of Sciences
2023

Institute of Biophysics
2023

Chengdu Third People's Hospital
2022

Southwest Jiaotong University
2022

Wuhan University of Science and Technology
2014

State Key Laboratory of Virology
2009

Wuhan University
2009

Previous observational studies have indicated that gut microbiota and metabolites may contribute to heart failure its risk factors. However, with the limitation of reverse causality confounder in studies, such relationship remains unclear. This study aims reveal causal effect on factors.This collected summary statistics regarding metabolites, failure, diabetes, hypertension, chronic kidney disease, myocardial infarction, atrial fibrillation, hypertrophic cardiomyopathy, dilated coronary...

10.3389/fnut.2022.899746 article EN cc-by Frontiers in Nutrition 2022-06-20

Abstract Continued emergence of SARS-CoV-2 variants concern that are capable escaping vaccine-induced immunity highlights the urgency developing new COVID-19 therapeutics. An essential mechanism for infection begins with viral spike protein binding to human ACE2. Consequently, inhibiting this interaction becomes a highly promising therapeutic strategy against COVID-19. Herein, we demonstrate ACE2-expressing lung spheroid cells (LSC)-derived exosomes (LSC-Exo) could function as prophylactic...

10.1038/s41467-024-45628-x article EN cc-by Nature Communications 2024-03-12

Currently, the development of effective diagnostic reagents as well treatments against Hepatitis C virus (HCV) remains a high priority. In this study, we have described an alive cell surface--Systematic Evolution Ligands by Exponential Enrichment (CS-SELEX) technique and screened functional ssDNA aptamers that specifically bound to HCV envelope surface glycoprotein E2. Through 13 rounds selection, CS-SELEX generated high-affinity aptamers, selected aptamer ZE2 demonstrated highest...

10.1371/journal.pone.0008142 article EN cc-by PLoS ONE 2009-12-02

Diabetic nephropathy (DN), as the one of most common complications diabetes, is generally diagnosed based on a longstanding duration, albuminuria, and decreased kidney function. Some patients with comorbidities diabetes other primary renal diseases have similar clinical features to DN, which defined non-diabetic disease (NDRD). It necessary distinguish between DN NDRD, considering they differ in their pathological characteristics, treatment regimes, prognosis. Renal biopsy provides gold...

10.3390/ijms241713560 article EN International Journal of Molecular Sciences 2023-09-01
Coming Soon ...